Fasinumab

Drug Profile

Fasinumab

Alternative Names: REGN 475; SAR 164877

Latest Information Update: 02 Jan 2017

Price : $50

At a glance

  • Originator Regeneron Pharmaceuticals; sanofi-aventis
  • Developer Regeneron Pharmaceuticals
  • Class Monoclonal antibodies; Non-opioid analgesics
  • Mechanism of Action Nerve growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pain
  • Phase II/III Back pain

Most Recent Events

  • 01 Nov 2016 Regeneron completes a phase II/III trial in Pain in USA (IV) (NCT02447276)
  • 20 Sep 2016 Regeneron Pharmaceuticals and Teva Pharmaceuticals enter into an agreement to develop and commercialise fasinumab worldwide, except in Japan, South Korea and nine other Asian countries
  • 02 May 2016 Efficacy and safety data from a phase II/III trial in Pain released by Regeneron Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top